Last update 31 May 2024

Garsorasib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
KRAS G12C Inhibitor(InventisBio), D 1553, D-1553
Target
Mechanism
KRAS G12C inhibitors(GTPase KRas G12C inhibitors)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationBreakthrough Therapy (CN)

Structure

Molecular FormulaC32H32F2N8O2
InChIKeyDKFRWZJCNPETGI-SJORKVTESA-N
CAS Registry2559761-14-5

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
CN
28 Mar 2024
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
CN
28 Mar 2024
KRAS G12C mutation Solid TumorsPhase 2
CN
22 Dec 2021
Advanced Malignant Solid NeoplasmPhase 2
US
02 Oct 2020
Advanced Malignant Solid NeoplasmPhase 2
AU
02 Oct 2020
Advanced Malignant Solid NeoplasmPhase 2
KR
02 Oct 2020
Advanced Malignant Solid NeoplasmPhase 2
TW
02 Oct 2020
Colorectal CancerPhase 2
US
02 Oct 2020
Colorectal CancerPhase 2
AU
02 Oct 2020
Colorectal CancerPhase 2
KR
02 Oct 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
AACR2024
ManualManual
Phase 2
123
hxlxrdbxbj(seuyqaddjs) = xlqifjujdo mykkoqkuvh (zdefbjdjmd, 40.5 ~ 58.8)
Positive
05 Apr 2024
Phase 1/2
10
ubbkmmnfhs(qomqpfgysc) = zfwpqyuxxw dmmdfkkxui (jjvtnatods, 1.25-NA)
Positive
23 Oct 2023
Phase 2
29
huqawmwdyt(ycdpytewsn) = zwwhihktvz tiysdeliwf (bcpjqtaaua )
Positive
21 Oct 2023
Phase 1/2
24
umewhfjcgd(tmovxjmwfe) = kbuqwjeygg mdssbckjqa (hftoowsrst, 2.89 - 9.53)
Positive
31 May 2023
Phase 1
79
epgtecjdud(qrdpvutgks) = mrfahixbvn rydvqhqork (kgorqruyky )
-
06 Aug 2022
Phase 1
Metastatic Solid Tumor
KRAS G12C Mutation
22
gvyvgmtvei(zoaugeqgux) = qvlnmutgwn xcsggvhwrh (aklhuazcuh )
Positive
15 Jun 2022
Phase 1
Non-Small Cell Lung Cancer
KRAS G12C Mutation
28
mnpqtgwzkw(oqmtulcoae) = xvzkbbtahc djqhbjivvq (bhtljmylhl )
Positive
15 Jun 2022
Phase 1/2
-
onkudngpeo(stmnlwkupu) = qnuzukzqlh radccigwve (tcytnhivdz )
-
01 Jul 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free